Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ferrone

Showing results (441-450 of 557) with videos related to

Pageof 56
Sort By:
The Journal of Clinical Investigation|January 1, 1991
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expressionC M D'Urso, Z G Wang, Y Cao, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
In vitro differentiation and antigenic changes in human melanoma cell linesL Guarini, M Temponi, G M Edwalds, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1980
Natural cytotoxicity and antibody-dependent cellular cytotoxicity of human lymphocytes depleted of HLA-DR bearing cells with monoclonal HLA-DR antibodiesA K Ng, F Indiveri, M A Pellegrino, et al.
Cancer Research|September 15, 1993
Differential effect of human and mouse beta 2-microglobulin on the induction and the antigenic profile of endogenous HLA-A and -B antigens synthesized by beta 2-microglobulin gene-null FO-1 melanoma cellsZ Wang, X Z Hu, R J Tatake, et al.
Annals of the New York Academy of Sciences|January 1, 1983
Antibody-dependent cell-mediated cytotoxicity using monoclonal antibodies reacting with CEAK Imai, T Sasanami, H Fujita, et al.
Seminars in Surgical Oncology|January 1, 1989
Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumorsM J O'Connell, Z J Chen, H Yang, et al.
Human Immunology|August 1, 1989
Signal transduction in lymphocyte activation through crosslinking of HLA class I moleculesL K Gilliland, N A Norris, L S Grosmaire, et al.
Annals of the New York Academy of Sciences|January 1, 1985
Antibodies as carriers of cancer chemotherapeutic agentsT Ghose, A H Blair, P Uadia, et al.
American Journal of Clinical Oncology|December 1, 1996
Melanoma-associated hypopigmentation: where are the antibodies?O Merimsky, Y Shoenfeld, E Baharav, et al.
International Immunology|February 1, 1994
HLA-B*3501-peptide interactions: role of anchor residues of peptides in their binding to HLA-B*3501 moleculesY Takamiya, C Schönbach, K Nokihara, et al.
Pageof 56

Showing results (441-450 of 557) with videos related to

Sort By:
Pageof 56
The Journal of Clinical Investigation|January 1, 1991
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expressionC M D'Urso, Z G Wang, Y Cao, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
In vitro differentiation and antigenic changes in human melanoma cell linesL Guarini, M Temponi, G M Edwalds, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1980
Natural cytotoxicity and antibody-dependent cellular cytotoxicity of human lymphocytes depleted of HLA-DR bearing cells with monoclonal HLA-DR antibodiesA K Ng, F Indiveri, M A Pellegrino, et al.
Cancer Research|September 15, 1993
Differential effect of human and mouse beta 2-microglobulin on the induction and the antigenic profile of endogenous HLA-A and -B antigens synthesized by beta 2-microglobulin gene-null FO-1 melanoma cellsZ Wang, X Z Hu, R J Tatake, et al.
Annals of the New York Academy of Sciences|January 1, 1983
Antibody-dependent cell-mediated cytotoxicity using monoclonal antibodies reacting with CEAK Imai, T Sasanami, H Fujita, et al.
Seminars in Surgical Oncology|January 1, 1989
Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumorsM J O'Connell, Z J Chen, H Yang, et al.
Human Immunology|August 1, 1989
Signal transduction in lymphocyte activation through crosslinking of HLA class I moleculesL K Gilliland, N A Norris, L S Grosmaire, et al.
Annals of the New York Academy of Sciences|January 1, 1985
Antibodies as carriers of cancer chemotherapeutic agentsT Ghose, A H Blair, P Uadia, et al.
American Journal of Clinical Oncology|December 1, 1996
Melanoma-associated hypopigmentation: where are the antibodies?O Merimsky, Y Shoenfeld, E Baharav, et al.
International Immunology|February 1, 1994
HLA-B*3501-peptide interactions: role of anchor residues of peptides in their binding to HLA-B*3501 moleculesY Takamiya, C Schönbach, K Nokihara, et al.
Pageof 56